GlassScriptPhysician profile
Harold Moses
NPI 1417031535
$438,198.04
in general payments reported to CMS, 2019-2025
14 companies · $22K in 2025
The $22K reported for 2025 was more than what 93% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139K · 2020: $36K · 2021: $50K · 2022: $55K · 2023: $87K · 2024: $50K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $97K · Consulting Fee: $30K · Honoraria: $16K · Travel and Lodging: $12K · Food and Beverage: $3,507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $97,370.00 |
| Consulting Fee | $30,299.13 |
| Honoraria | $15,800.00 |
| Travel and Lodging | $11,506.20 |
| Food and Beverage | $3,507.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $110,341.17 | 2019-2024 | Tysabri, Vumerity, Plegridy |
| Emd Serono, INC. | $78,106.64 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $50,104.30 | 2019-2024 | Ultomiris |
| Genentech USA, INC. | $45,041.93 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $32,427.16 | 2019-2024 | |
| Tg Therapeutics, INC. | $30,620.80 | 2022-2025 | |
| Celgene Corporation | $28,584.46 | 2019-2025 | |
| Horizon Therapeutics Plc | $28,245.03 | 2021-2023 | Uplizna |
| E.R. Squibb & Sons, L.L.C. | $26,016.32 | 2021-2025 | |
| Genzyme Corporation | $4,854.83 | 2019 | |
| Genentech, INC. | $1,640.40 | 2021-2022 | |
| Ares Trading Sa | $1,590.00 | 2023 | Evobrutinib |
| Janssen Pharmaceuticals, INC | $625.00 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harold Moses listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.